Most Read Articles
Audrey Abella, 26 Jul 2017
Upstream use of the P2Y12 receptor antagonist ticagrelor provides benefit over clopidogrel in patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS) with a relatively rapid time to angiography, according to a post hoc analysis of the PLATO* trial.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

17 Jun 2019
Podcast: Dr Sara Hurvitz highlights that the addition of ribociclib to endocrine therapy improved overall survival in premenopausal women with HR+, HER2- advanced breast cancer, according to the MONALEESA-7 trial.
Roshini Claire Anthony, 11 Jun 2018

Patients who received a combination of ticagrelor plus aspirin within 24 hours of undergoing coronary artery bypass grafting (CABG) had significantly improved saphenous vein graft patency rates 1 year post-procedure compared with those who only received aspirin, according to findings of the DACAB* trial.

Continuous MTX use lowers risk of CV events in patients with rheumatoid arthritis

17 May 2019

Recent continuous use of methotrexate (MTX) is associated with a 20-percent decrease in cardiovascular events (CVE) in patients with early-onset rheumatoid arthritis (RA), a recent study has shown. In addition, greater MTX use in the first year of cohort entry appears to lower the risk of CVE.

CVE occurred in 3,294 (13.7 percent) patients (28.5 events per 1,000 patient-years; 95 percent CI, 27.6–29.5) over 115,453 patient-years. Multivariate analyses revealed that the model assessing time-varying continuous use in the most recent year produced the best fit.

There was an association between increasing recent MTX and lower CVE risks (hazard ratio [HR] for continuous use vs no use in past 12 months, 0.79; 95 percent CI, 0.70–0.88; p<0.0001). Greater MTX use in the first year after cohort entry also conferred protection against CVE (HR, 0.84; 0.72–0.96; p=0.0048), but this effect decreased with increasing follow-up.

On the other hand, there was no clear association between longer MTX use during the entire follow-up and CVE risk (HR, 0.98; 0.95–1.01; p=0.1441).

This study analysed an inception cohort of 23,994 patients with RA diagnosed after their 65th birthday. Multivariable Cox regression models were fit to examine the associations between time-varying MTX use and time to CVE, controlling for other risk factors.

The investigators used alternative models to assess the cumulative duration of MTX use over the first year, previous year (recent use) and entire duration of follow-up. They also determined whether the strength of the association varied over time.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 26 Jul 2017
Upstream use of the P2Y12 receptor antagonist ticagrelor provides benefit over clopidogrel in patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS) with a relatively rapid time to angiography, according to a post hoc analysis of the PLATO* trial.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

17 Jun 2019
Podcast: Dr Sara Hurvitz highlights that the addition of ribociclib to endocrine therapy improved overall survival in premenopausal women with HR+, HER2- advanced breast cancer, according to the MONALEESA-7 trial.
Roshini Claire Anthony, 11 Jun 2018

Patients who received a combination of ticagrelor plus aspirin within 24 hours of undergoing coronary artery bypass grafting (CABG) had significantly improved saphenous vein graft patency rates 1 year post-procedure compared with those who only received aspirin, according to findings of the DACAB* trial.